Physician profile
Constance C Mere
NPI 1205945565
$2,649.22
in general payments reported to CMS, 2019-2025
23 companies · $607 in 2025
The $607 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.06 · 2020: $15.17 · 2021: $371 · 2022: $331 · 2023: $685 · 2024: $542 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.84 |
| Education | $244.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $517.45 | 2022-2025 | |
| Vifor Pharma, INC. | $327.37 | 2019-2024 | Veltassa, Korsuva |
| Fresenius USA Marketing, INC. | $297.19 | 2021-2025 | Velphoro, Velphoro |
| Glaxosmithkline, LLC. | $226.73 | 2023-2025 | Benlysta, Jesduvroq |
| Ardelyx, INC. | $222.57 | 2023-2024 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $222.41 | 2019-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $152.55 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $136.83 | 2021-2025 | Rayaldee |
| Amgen INC. | $94.12 | 2021-2025 | Krystexxa, Tavneos |
| Ani Pharmaceuticals, INC. | $63.00 | 2024-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $61.86 | 2022-2023 | Tarpeyo |
| Akebia Therapeutics INC | $48.66 | 2024-2025 | Vafseo |
| Viatris Specialty LLC | $45.35 | 2025 | Yupelri |
| Travere Therapeutics, INC. | $40.58 | 2024 | |
| Genzyme Corporation | $37.93 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leadiant Biosciences, INC. | $26.67 | 2024 | Cystaran |
| Corcept Therapeutics | $25.85 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.72 | 2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $22.34 | 2022 | |
| Novo Nordisk INC | $22.10 | 2024 | Rivfloza |
| Biomerieux INC | $17.77 | 2019 | |
| Outset Medical INC | $15.17 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Constance Mere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.